Vivo Opportunity Fund Holdings L.P. 13D and 13G filings for Soleno Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-05 6:37 pm Sale | 2024-08-27 | 13G | Soleno Therapeutics, Inc. SLNO | Vivo Opportunity Fund Holdings L.P. | 6,291,851 16.200% | -1,025,000 (-14.01%) | Filing |
| 2024-05-01 1:07 pm Sale | 2024-04-29 | 13D | Soleno Therapeutics, Inc. SLNO | Vivo Opportunity Fund Holdings L.P. | 7,316,851 22.500% | -1,101,242 (-13.08%) | Filing |
| 2023-10-11 4:30 pm Unchanged | 2023-10-02 | 13D | Soleno Therapeutics, Inc. SLNO | Vivo Opportunity Fund Holdings L.P. | 8,418,093 30.500% | 0 (Unchanged) | Filing |
| 2023-06-01 5:00 pm Purchase | 2023-05-25 | 13D | Soleno Therapeutics, Inc. SLNO | Vivo Opportunity Fund Holdings L.P. | 8,418,093 50.800% | 8,418,093 (New Position) | Filing |